Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate, Diquafosol Sodium, and Moxifloxacin Hydrochloride eye drops, as well as Iodized lecithin capsules.
